Moderna Executive and Leadership Team

Jamey Mock, the Chief Financial Officer at Moderna, directs all global financial operations and capital allocation strategies. Overseeing the fiscal health of the organization, the Chief Financial Officer ensures alignment between mRNA research investments and long-term shareholder value. This leadership role involves managing complex budgetary frameworks across North American and international markets to support the rapid scaling of vaccine production. By optimizing capital structures, Jamey Mock directly impacts the ability of the company to fund high-risk, high-reward clinical trials. Ultimately, Mock secures the financial stability required to maintain the competitive edge of the firm in the biotechnology sector. Through rigorous oversight of financial reporting and risk management, the Chief Financial Officer provides the necessary resources for the scientific teams to continue pioneering mRNA medicine while maintaining operational efficiency across all global business units.

Kei Kaneda, the Representative Director & President at Moderna, directs the overall corporate strategy and regional governance for the organization. Overseeing the expansion of operations within key international markets, the Representative Director & President ensures that the mission of the company remains consistent across all geographic territories. This leadership role involves fostering relationships with local regulatory bodies and healthcare partners to facilitate the adoption of mRNA medicine. By providing high-level guidance to the executive team, Kei Kaneda directly impacts the growth trajectory of the firm. Ultimately, Kaneda secures the long-term success of the company by aligning regional activities with the global vision of transforming disease prevention. Through the management of corporate governance and strategic partnerships, the Representative Director & President ensures that the organization maintains its commitment to scientific excellence and operational integrity on a global scale.

Jeffrey Salling, the Chief of Staff & Operations Senior Director, Legal at Moderna, architects the operational workflows that bridge legal compliance with corporate strategy. Overseeing the integration of regulatory requirements into daily business processes, the Chief of Staff & Operations Senior Director, Legal ensures that all mRNA development initiatives adhere to international standards. This leadership role involves coordinating cross-functional teams to streamline decision-making processes and mitigate legal risks associated with global clinical trials. By refining internal governance structures, Jeffrey Salling directly impacts the speed at which new medical solutions reach the market. Ultimately, Salling maintains the integrity of the corporate legal framework while supporting the rapid expansion of the product pipeline. Through the management of complex legal operations, the Chief of Staff & Operations Senior Director, Legal facilitates seamless collaboration between the executive board and the scientific departments to drive organizational success.

Sam Ismail, the Chief Marketing Officer & Senior Analyst at Moderna, directs the strategic positioning of mRNA-based therapies within the global healthcare landscape. Overseeing market intelligence and data-driven growth initiatives, the Chief Marketing Officer & Senior Analyst ensures that the value proposition of new vaccines reaches key stakeholders effectively. This leadership role involves analyzing complex market trends to identify emerging opportunities for therapeutic expansion across diverse patient populations. By synthesizing clinical data into actionable commercial strategies, Sam Ismail directly impacts the adoption rates of innovative medical treatments. Ultimately, Ismail drives the market presence of the company by aligning commercial efforts with the evolving needs of the global medical community. Through the rigorous analysis of competitive dynamics, the Chief Marketing Officer & Senior Analyst supports the overarching mission of transforming human health through advanced technology and scientific excellence.

Paula Rodrguez, the Senior Chief Marketing Officer, Operations & Specialist at Moderna, architects the operational infrastructure required to execute large-scale commercial campaigns. Overseeing the logistical execution of marketing programs, the Senior Chief Marketing Officer, Operations & Specialist ensures that promotional activities remain consistent with the scientific rigor of the company. This leadership role involves managing the operational complexities of launching new mRNA products across diverse international regions. By optimizing the internal processes that support commercial outreach, Paula Rodrguez directly impacts the efficiency of the go-to-market strategy. Ultimately, Rodrguez secures the operational readiness of the marketing department to handle the rapid introduction of new medical solutions. Through the coordination of specialized marketing teams, the Senior Chief Marketing Officer, Operations & Specialist facilitates the seamless delivery of information to healthcare providers and patients, reinforcing the market position of the firm.

Michael Aihe, the Manager, Chief Marketing Officer Planning, Supply Chain at Moderna, directs the integration of supply chain logistics with commercial planning to ensure product availability. Overseeing the alignment of manufacturing output with market demand, the Manager, Chief Marketing Officer Planning, Supply Chain ensures that mRNA vaccines reach patients without disruption. This leadership role involves managing the complex flow of information between production facilities and commercial teams to optimize inventory levels. By synchronizing supply chain capabilities with marketing forecasts, Michael Aihe directly impacts the reliability of the distribution network. Ultimately, Aihe supports the mission of the company by ensuring that the supply chain remains responsive to the needs of the global healthcare market. Through the strategic management of supply chain planning, the Manager, Chief Marketing Officer Planning, Supply Chain provides the operational foundation necessary for the successful commercialization of new medical treatments.

Sameh Ismail, the Chief Marketing Officer & Senior Analyst at Moderna, directs the long-term forecasting and strategic planning for the mRNA product portfolio. Overseeing the evaluation of market performance metrics, the Chief Marketing Officer & Senior Analyst ensures that commercial strategies remain agile in the face of changing medical landscapes. This leadership role involves conducting deep-dive analyses into patient outcomes and market penetration to inform future investment decisions. By providing critical insights into the competitive environment, Sameh Ismail directly impacts the strategic direction of the commercial division. Ultimately, Ismail strengthens the market impact of the company by identifying high-growth areas for therapeutic development. Through the application of advanced analytical models, the Chief Marketing Officer & Senior Analyst supports the executive team in making informed decisions that advance the goal of improving human health through scientific innovation and technological advancement.